Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 12Pancreatic Neoplasms 6Cholangiocarcinoma 4Cirrhosis, Familial, with Pulmonary Hypertension 3Esophageal Neoplasms 2Biliary Tract Neoplasms 2Stomach Neoplasms 1Pathologic Complete Response 1Pancreatic Cancer Resectable 1PDAC - Pancreatic Ductal Adenocarcinoma 1Neoplasms, Second Primary 1Neoplasm, Residual 1Neoplasm Metastasis 1Locally Advanced Low Rectal Adenocarcinoma 1Liver Neoplasms 1Liver Metastases of Colorectal Cancer 1Gastroesophageal Junction Cancer 1Esophageal Squamous Cell Carcinoma 1Efficacy and Safety 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1CRC 1Biliary Cancer Metastatic 1Appendiceal Neoplasms 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

pembrolizumab 1Oxaliplatin 1Leucovorin 1Fluorouracil 1Drug Therapy 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Gastroesophageal Junction Cancer × Leucovorin × Clear all
NCT06411171 2024-05-17

Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:

Xijing Hospital of Digestive Diseases

Phase 3 Not yet recruiting
36 enrolled
Gastrointestinal

Gastroesophageal Junction Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡